What does this research mean for the field?

Vericiguat is being evaluated for its efficacy in managing worsening heart failure among patients enrolled in the VERINA Study. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to outline the study design and initial characteristics of participants in the VERINA trial focusing on vericiguat for heart failure.

January 10, 2026Cardiology and Therapy0 citationsOpen Access

Study Design and Baseline Characteristics of the VERINA Study: Phase IV Evidence of Vericiguat for Worsening Heart Failure Management

JAJabir Abdulakutty AAAtul Abhyankar SSSandeep SethAll India Institute of Medical Sciences Raipur

Key Result

Vericiguat is being evaluated in the VERINA Study for its efficacy in managing worsening heart failure among patients enrolled in the clinical trial.

Key Points

The aim is to outline the study design and initial characteristics of participants in the VERINA trial focusing on vericiguat for heart failure.
Conducted a Phase IV clinical trial
Collected baseline data on participant characteristics
Utilized a clinical trials registry for documentation
Detailed participant baseline characteristics were recorded
The trial aims to establish vericiguat's effectiveness in heart failure management

Structured PICO

Population

205 Indian adults (mean age 58.0, 73.7% male) with chronic HFrEF (LVEF <45%) and a recent worsening heart failure event, who were vericiguat-naïve.

Intervention

Vericiguat starting at 2.5 mg once daily, uptitrated every 2 weeks to a target maintenance dose of 10 mg once daily, added to standard heart failure therapy.

Outcome

Composite of cardiovascular death or first heart failure hospitalizationcomposite

In a real-world Indian cohort of patients with worsening HFrEF, vericiguat was successfully titrated to the target dose of 10 mg in over 90% of patients without new safety concerns.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Clinical Trials Registry of India (CTRI/2022/11/047636).

问 AI

Bookmark

View Full Paper